Generex Biotechnology Corporation announced that new members have joined the Scientific Advisory Board (SAB) of its Antigen Express, Inc. for the company's AE37 breast cancer vaccine. The following investigators join Dr. Gabriel N. Hortobagyi, MD, FACP (University of Texas MD Anderson Cancer Center), Dr. Kathy D. Miller, MD (Indiana University School of Medicine Melvin and Bren Simon Cancer Center), and Dr. Hope S. Rugo, MD (University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center) on the SAB: Dr. Keith L. Knutson. PhD Associate Professor, Department of Immunology Mayo Clinic: Dr. Knutson's current interests and research focus on the immunology and immunotherapy of breast and ovarian cancers, both the basic immunobiology and clinical translation, including clinical trials. His laboratory research on cancer vaccines focuses on augmenting CD4 helper T cell immunity using peptide epitopes. Dr. James J. Mule Moffitt Cancer Center: Dr. Mule currently serves on the advisory boards of several NCI-designated Cancer Centers and was a member of the NCI Director's Board of Scientific Counselors (BSC-A, clinical). Dr. Mule has or is currently serving on the Scientific/Medical Advisory Boards of numerous privately or publicly held companies and has been or is a consultant to many others.